Remyelination of the demyelinated CNS: the case for and against transplantation of central, peripheral and olfactory glia.
Although originally developed as a research tool for studying glial-glial and glial-axonal interactions, the technique of transplanting glial cell into the central nervous system has more recently been employed as a potential means for repairing persistent demyelination in clinical disease. It has now been clearly established using various experimental models that oligodendrocyte lineage cells, Schwann cells and olfactory ensheathing cells can all produce new myelin sheaths around demyelinated or amyelinated axons following transplantation. However, this property alone does not necessarily mean that transplantation of these cells into demyelinated lesions in clinical disease will be successful. This article considers some of the properties that would be required of a transplanted myelinogenic cell and assesses the advantages and disadvantages of the currently available cell types.
Franklin
Robin J M
RJ
Department of Clinical Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge, UK. rjf1000@cam.ac.uk
D000818:Animals; D016380:Brain Tissue Transplantation / Q000009:adverse effects / Q000379:methods* / Q000639:trends; D020278:Demyelinating Autoimmune Diseases, CNS / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D004195:Disease Models, Animal; D006801:Humans; D009186:Myelin Sheath / Q000378:metabolism / Q000473:pathology; D009416:Nerve Regeneration / Q000502:physiology*; D009830:Olfactory Bulb / Q000166:cytology / Q000378:metabolism / Q000637:transplantation*; D009836:Oligodendroglia / Q000166:cytology / Q000378:metabolism / Q000637:transplantation*; D012583:Schwann Cells / Q000166:cytology / Q000378:metabolism / Q000637:transplantation*; D033581:Stem Cell Transplantation; D013234:Stem Cells / Q000166:cytology / Q000378:metabolism